HB3794 is a prescription-drug bill that makes several changes to Illinois insurance, pharmacy benefit manager (PBM), and pharmacy practice law. Its central PBM provision requires a covered individual’s cost sharing for each prescription drug to be calculated at the point of sale using a price reduced by at least 80% of rebates received or expected to be received in connection with that drug. The bill also bars health insurers and their agents from disclosing actual rebate amounts by product, therapeutic class, manufacturer, or pharmacy, and treats that information as confidential and exempt from disclosure under the Freedom of Information Act.
The bill also revises Illinois rules for biosimilar substitution. Under the Pharmacy Practice Act, a pharmacist could substitute a biological product if the product is either the reference product or an FDA-approved biosimilar, rather than only an FDA-determined interchangeable biological product. The bill keeps other substitution safeguards in place, including prescriber override and patient notification, and makes conforming changes to related statutory language.
Impact
HB3794 would amend the Illinois Insurance Code, the Freedom of Information Act, and the Pharmacy Practice Act. In practice, it would change how prescription drug cost sharing is calculated for insured patients, increase confidentiality protections around rebate data, and expand the circumstances under which pharmacists may substitute biosimilar products. It also reinforces existing PBM contract rules, including maximum allowable cost list requirements, audit and disclosure rights for plan sponsors, anti-retaliation protections for pharmacists and pharmacies, and special provisions for 340B entities and pharmacies.
Sentiment
No committee transcripts or recorded votes were provided, so there is no documented legislative debate or vote history to gauge formal sentiment. Based on the bill text, the measure appears oriented toward lowering patient out-of-pocket costs and increasing transparency or accountability in PBM contracting, while also protecting rebate information as confidential. The biosimilar language suggests a pro-substitution, access-oriented approach to prescription drug dispensing.
Contention
The most likely points of contention are the PBM rebate provisions and the confidentiality rules. Supporters may favor the requirement that rebates be passed through to reduce patient cost sharing, while opponents could object to the mandated 80% rebate pass-through, the treatment of rebate data as trade secret/confidential, or the operational burden on insurers and PBMs. The biosimilar substitution change may also draw scrutiny from prescribers, manufacturers, or pharmacists because it broadens substitution authority from interchangeable biologics to FDA-approved biosimilars, though the bill retains prescriber and patient protections. The 340B nondiscrimination provisions could also be controversial for payers and PBMs that argue they need flexibility in network and reimbursement design.